Skip to content

Clinical Efficacy of Platelet rich plasma and conventional drug injection in the treatment of early osteoarthritis of the knee

Clinical Efficacy of Platelet rich plasma and conventional drug injection in the treatment of early osteoarthritis of the knee

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038635
Enrollment
Unknown
Registered
2020-09-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

experimental group:PRP is injected into the joint cavity once a week for 4 weeks on the basis of health education and conventional quadriceps training methods
control group:Sodium hyaluronate is injected into the joint cavity once a week for 4 weeks on the basis of health education and routine quadriceps training

Sponsors

General Hospital of Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for knee osteoarthritisGuidelines for the Diagnosis and Treatment of Osteoarthritis, 2018 edition, Joint Surgery Group, Osteoscience Branch, Chinese Medical Association; 2. Kellgren-Lawrence grade II - IV; 3. Between the ages of 40 and 75; 4. BMI is less than 30; 5. Knee osteoarthritis has not been treated in any way in recent 3 months 6. Good compliance, willing to cooperate with the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Autoimmune arthropathy; 2. Patients with pain in the acute stage of knee osteoarthritis; 3. Patients with bleeding tendency or coagulation dysfunction; 4. Infection, surgery and radiation treatment of the knee within three months; 5. Injected glucocorticoid or sodium hyaluronate within 3 months; Infection of the skin in the injection area; 6. Pregnant women or lactating women; 7. imaging examination before treatment KL class reach IV; 8. Suffering from severe organ failure, severe cardiovascular and cerebrovascular diseases, blood diseases and infectious diseases; 9. Other study participants who are participating in and influencing the results of this study.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale, VAS;Western Ontario and McMaster University Osteoarthritis Score, WOMC;

Secondary

MeasureTime frame
interleukin-6;ADL score;erythrocyte sedimentation rate;C-reactive protein;x-ray examination;

Countries

China

Contacts

Public ContactLin Ruizhu

General Hospital of Ningxia Medical University

linruizhu05@126.com+86 13519217785

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026